SMLR Director Gets 1,125 Options at $41.04 – Routine Form 4 Filing
Semler Scientific, Inc. (SMLR) – Form 4 Overview Director Natalie Brunell reported the grant of a single derivative security on 25 June 2025.
Rhea-AI Filing Summary
Semler Scientific, Inc. (SMLR) – Form 4 Overview
Director Natalie Brunell reported the grant of a single derivative security on 25 June 2025. The filing covers a stock option to purchase 1,125 shares of common stock at an exercise price of $41.04 per share. The instrument is classified as an acquisition (transaction code “A”).
Vesting schedule: 1/6 of the option (≈188 shares) vested immediately on the grant date, with the remaining 5/6 vesting in equal monthly tranches, resulting in full vesting six months after 25 June 2025. The option expires on 25 June 2035.
Post-transaction holdings: Ms. Brunell now beneficially owns 1,125 derivative securities directly. No non-derivative (outright share) transactions were reported.
No 10b5-1 trading plan was indicated, and no other insider participated in this filing. The grant appears to be a routine director compensation award and does not include any immediately exercisable common-stock sales or purchases.
Positive
- Alignment of interests: Granting equity-based compensation to a director ties board member incentives to shareholder value.
Negative
- None.
Insights
TL;DR: Routine director option grant; aligns incentives, immaterial size.
The Form 4 discloses a typical equity-based compensation grant to a non-executive director. With only 1,125 options—well below 1% of Semler’s 7 million-plus outstanding shares—the award has negligible dilution. A six-month vesting cliff accelerates alignment but is shorter than the one-year vesting often seen, suggesting the board favors quicker ownership for outside directors. No 10b5-1 plan is flagged, so subsequent sales would require new disclosure. Overall governance impact is neutral: it follows normal practice and provides transparency without altering control dynamics.
TL;DR: Neutral—small option grant, no cash impact, no signal on fundamentals.
Financially, the option strike of $41.04 sits near recent market levels, indicating a fair-market grant rather than an in-the-money incentive. Because the option expires in 2035, it adds long-dated potential dilution of 0.016% (1,125 ÷ ~7 million shares). There is no immediate P&L expense disclosure here, but GAAP option expense will be minimal. Importantly, the filing does not signal insider confidence via open-market buying; it merely documents standard compensation. For valuation models, the incremental dilution is immaterial, and there is no read-through to earnings or revenue outlook.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 1,125 | $0.00 | $0.00 |
Footnotes (1)
- F1. The shares underlying the option shall vest and become exercisable as follows: 1/6th of the underlying shares shall vest on the grant date, following which 1/6th of the underlying shares shall vest on a monthly basis thereafter such that it is vested in full 6 months after the grant date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Semler Scientific (SMLR) report on 25 June 2025?
How does the SMLR option granted to Natalie Brunell vest?
What is the expiration date of the newly granted Semler Scientific option?
Did the Form 4 indicate a Rule 10b5-1 trading plan for the director?
How many derivative securities does Natalie Brunell own after this transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.
